European marketing authorisation for Aivlosin® WSG in pigs for treatment and metaphylaxis of M. hyopneumoniae
29 June 2020
European marketing authorisation for Aivlosin® WSG in pigs for treatment and metaphylaxis of M. hyopneumoniae
ECO Animal Health Group plc (the “Group”) is pleased to announce that, as anticipated, a marketing authorisation has been received from the European Medicines Agency (EMA) for the use of Aivlosin® 625 mg/g Water Soluble Granules (WSG) for the treatment and metaphylaxis (disease control) of Mycoplasma hyopneumoniae in pigs.
The Group had previously announced a positive opinion on 22nd May 2020 with the marketing authorisation expected within two months.
Mycoplasma hyopneumoniae is the most common primary pathogen in pig respiratory disease and is a key instigator of secondary bacterial and viral pathogens. The EU market accounts for approximately 15 per cent of the world’s swine market.
Aivlosin®, ECO’s patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.
Marc Loomes, CEO, commented:
“We are very pleased that this marketing authorisation has been received after only one month and we look forward to offering Aivlosin® for the treatment of Mycoplasma infections in this important market. This further approval underlines the value of Aivlosin® for the safe and highly effective treatment of a range of diseases and infections.”